Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Kyowa Kirin Sticks to Long-Term Targets despite Rocatinlimab Setback
Kyowa Kirin will maintain the medium- to long-term financial targets it announced in February despite discontinuing all clinical trials of its atopic dermatitis drug candidate rocatinlimab, President and COO Abdul Mullick said at an investor briefing on March 4. Takeyoshi…
To read the full story
Related Article
- Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
March 4, 2026
- Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
February 12, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
BUSINESS
- Ono Sets Course for Growth Beyond Opdivo Patent Cliff
March 25, 2026
- Fuji, Richter Strike Co-Development Pact in Women’s Health
March 25, 2026
- ASKA Inks AI Target Discovery Pact with Insilico in Women’s Health
March 25, 2026
- Shionogi to Fully Acquire Sleep Disorder JV SASS
March 25, 2026
- Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…